Bivalent TRK Degrader Compound for Targeted Protein Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving tropomyosin receptor kinase (TRK) proteins lack effective targeting and degradation mechanisms, limiting therapeutic options for diseases associated with TRK mutations or overactivity.
Innovation Solution
Development of bivalent compounds comprising a TRK ligand conjugated to a degradation tag, specifically a TRK kinase inhibitor linked to a ubiquitin ligase-targeting moiety, to selectively target and degrade TRK proteins, utilizing a linker moiety and various chemical structures to enhance binding and degradation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TRK kinase inhibitors are used, then TRK activity is inhibited, but the inhibitors lack targeted degradation capability and have limited therapeutic efficacy
Solution Approach 1:
The patent combines a TRK kinase inhibitor (first moiety) with a degradation tag (second moiety) into a single bivalent compound. The inhibitor portion binds to and inhibits TRK kinase activity, while the degradation tag recruits ubiquitin ligase to facilitate proteasomal degradation of TRK protein. This merging of inhibition and degradation functions into one molecule resolves the contradiction by providing both kinetic inhibition and ultimate protein removal, thereby enhancing therapeutic efficacy without requiring separate agents.
Solution Approach 2:
The bivalent compound functions as a composite molecular structure where two distinct functional moieties are covalently linked. The first moiety (TRK kinase inhibitor) and second moiety (degradation tag) maintain their individual functions while working synergistically. The inhibitor portion provides immediate functional blockade, while the degradation tag enables long-term protein reduction through targeted degradation pathways, creating a composite therapeutic agent with enhanced and multifaceted activity.
2Adaptability or versatility
If a bivalent compound structure is designed to enable both binding and degradation, then targeted degradation capability is achieved, but the molecular complexity increases
Solution Approach 1:
The bivalent compound is segmented into two distinct functional moieties: a first moiety responsible for TRK binding and inhibition, and a second moiety responsible for degradation tag function. This segmentation allows each portion to be optimized independently for its specific function while maintaining overall molecular integrity. The clear functional division simplifies the design process despite the increased molecular complexity, as each segment can be selected or designed based on established pharmacophores or degradation tag structures.
Solution Approach 2:
A linker moiety serves as an intermediary connecting the TRK kinase inhibitor and the degradation tag. This linker is carefully designed to provide appropriate spatial separation and orientation, ensuring that both functional moieties can operate independently without steric interference. The linker acts as a flexible bridge that maintains the structural integrity of the bivalent compound while allowing each functional domain to interact with its respective target (TRK kinase and ubiquitin ligase) effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bivalent compounds effectively bind to TRK proteins and induce targeted degradation, offering a novel approach to treating TRK-related diseases by enhancing the specificity and efficacy of TRK inhibition.
Implementation Method 1
the TRK ligand is capable of binding to a TRK protein comprising TRK, a TRK mutant, TRK deletion, or a TRK fusion protein
Implementation Method 2
the degradation tag binds to an ubiquitin ligase
Implementation Method 3
The bivalent compounds effectively bind to TRK proteins and induce targeted degradation
Data Source
AI summary
This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.